KU Medical Center part of COVID-19 clinical trial
September 23, 2020
KANSAS CITY, Kan. (AP) — The University of Kansas Medical Center is part of a nationwide clinical trial looking into different treatments for patients with mild to moderate symptoms of the coronavirus who do not require hospitalization.
KCUR-FM reports that the first treatment will involve the use of monoclonal antibodies that target the spike proteins of COVID-19, using a drug made by Eli Lilly. Monoclonal antibodies are engineered versions of the same virus-fighting antibodies that the body naturally produces.
The clinical trial is one of at least 40 around the country that seeks to rec...